Physician profile
Molly Marks
NPI 1306076781
$1,126.22
in general payments reported to CMS, 2019-2025
13 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $291 · 2023: $372 · 2024: $152 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $432.62 | 2021-2025 | Bexsero, Pediarix, Rotarix |
| Ironshore Pharmaceuticals INC. | $172.42 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $140.98 | 2021-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $69.29 | 2022-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Kaleo, INC. | $53.51 | 2021-2023 | Auvi-Q |
| Collegium Pharmaceutical, INC. | $47.95 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $39.27 | 2022-2025 | |
| Seqirus USA INC | $38.50 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $33.02 | 2023 | Flumist Quadrivalent |
| Neurelis, INC. | $32.66 | 2025 | Valtoco |
| Sobi, INC | $29.12 | 2023 | |
| Adlon Therapeutics L.P. | $22.19 | 2021 | |
| Neos Therapeutics, LP | $14.69 | 2024 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.